The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

This website uses cookies. By continuing to use this website you consent to using cookies. For more information about cookies and how we use them, please see our Privacy Policy.

Maquet announces peer-reviewed publication showing larger capacity intra-aortic balloon pumps to have greater hemodynamic effect on patients


Retrospective Study Examines 50 cc IABPs versus 40 cc IABPs in Real World Practice

Maquet Getinge Group announced today the publication of a manuscript describing the exploration of the hemodynamic effects of the newer, larger-capacity 50cc intraaortic balloon pumps (IABPs) versus 40cc IABPs in real-world clinical practice. The paper, titled "Hemodynamic Effects of Standard Versus Larger-Capacity Intraaortic Balloon Counterpulsation Pumps," appears in the April 2015 volume of The Journal of Invasive Cardiology.

The study, led by Navin K. Kapur, MD, Assistant Director of the Interventional Cardiology Center at Tufts Medical Center; Investigator at Tufts Molecular Cardiology Research Institute; and Assistant Professor at Tufts University School of Medicine, was a retrospective examination of demographic, hemodynamic, and laboratory data in 26 consecutive subjects treated with a 50cc IABP and compared with 26 patients receiving a 40cc IABP between 2012 and 2013. IABP tracings were analyzed within 24 hours of implantation in all patients. Pulmonary artery catheter data were available before and after IABP implantation in 20 subjects.

The study found that the larger-capacity 50cc IABPs provides greater diastolic augmentation and systolic unloading compared with the 40cc IABP. In the analysis, recipients of the 50cc IABP were observed to achieve a greater reduction in cardiac filling pressures and increased cardiac output compared with the 40 cc group. It was also observed that a greater number of patients achieved a reduction in systolic pressure in the 50cc IABP group compared with the 40cc IABP group -- the magnitude of systolic unloading correlates directly with the magnitude of diastolic augmentation and inversely with pulmonary artery occlusion pressure. Taken together, these observations suggest that the 50cc IABP may achieve a greater hemodynamic effect compared with the standard 40cc IABP.

"The intra-aortic balloon pump remains the most widely used form of mechanical hemodynamic support for cardiac patients because of their clinical efficacy and safety profile across a broad range of patient care scenarios," said Dr. Marc Cohen, Chief of the Division of Cardiology at Newark Beth Israel Medical Center, Newark, NJ and Professor of Medicine at Rutgers-New Jersey Medical School, “Given IABPs’ continuing role in the management of high-risk patients with and without cardiogenic shock, new research into the newer 50cc balloon is key to better understanding the role of IABPs in the modern era of acute cardiovascular care. The 50cc IABP recipients demonstrated higher augmented diastolic blood pressure and greater systolic unloading compared to 40cc IAB patients which is encouraging and warrants more research into whether this larger capacity balloon offers meaningful morbidity and mortality benefits.”

Pierluca Lombardi M.D., Chief Medical Officer, Maquet Cardiovascular, said, “Maquet has long been recognized as the leader in IABP therapy, offering trusted products while also providing innovations and improvements. We strive to improve patient’s response to our therapy, and the 50cc IAB catheter provides a more tailored approach to meet patient’s anatomical and physiologic needs. We are excited to see this new research on our 50cc balloon as it will help the field gain greater insight into its role in the treatment of high risk patients.”

For online access to the full paper, visit:

About Maquet

Maquet, a trusted partner for hospitals and physicians for more than 175 years, is a global leader in medical systems. The company offers innovative therapy solutions and infrastructure capabilities for high-acuity areas within the hospital - including the operating room (OR), hybrid OR/cath lab, and intensive care unit (ICU) - as well as intra- and inter-hospital patient transport. Additionally, Maquet develops intelligent and sustainable room concepts that exceed the expectations of modern hospitals, working in close cooperation with customers, production engineers and architects to integrate high quality products and services.

Headquartered in Rastatt, Germany, Maquet is the largest subsidiary of the publicly listed GETINGE Group AB of Sweden. Maquet generated about 1.55 billion Euros in 2014, representing more than half of the Getinge Group's annual revenue of 2.93 billion Euros. Maquet has 7,000 employees and provides 53 international sales and service organizations, as well as a network of more than 300 sales partners.